- Home
- ESAB vs MMED Comparison
ESAB vs MMED Comparison
Compare ESAB & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | MMED |
|---|---|---|
| Founded | 1904 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.5B |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ESAB | MMED |
|---|---|---|
| Price | $87.96 | $19.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $138.56 | $22.56 |
| AVG Volume (30 Days) | 579.8K | ★ 1.2M |
| Earning Date | 05-07-2026 | 06-03-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | $2,842,555,000.00 | ★ $3,102,000,000.00 |
| Revenue This Year | $6.21 | $15.99 |
| Revenue Next Year | $5.33 | $10.00 |
| P/E Ratio | $67.32 | ★ N/A |
| Revenue Growth | 3.71 | ★ 14.25 |
| 52 Week Low | $82.19 | $10.65 |
| 52 Week High | $137.42 | $19.93 |
Technical Indicators
Market Signals| Indicator | ESAB | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 70.02 |
| Support Level | $82.55 | $10.68 |
| Resistance Level | $94.18 | N/A |
| Average True Range (ATR) | 4.08 | 0.76 |
| MACD | 0.32 | 0.09 |
| Stochastic Oscillator | 30.84 | 87.79 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2025.
About MMED MiniMed Group Inc. Common Stock
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.